Guardant Health (MEX:GH) FCF Margin % : -41.32% (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Guardant Health FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Guardant Health's Free Cash Flow for the three months ended in Dec. 2024 was MXN-1,739 Mil. Guardant Health's Revenue for the three months ended in Dec. 2024 was MXN4,209 Mil. Therefore, Guardant Health's FCF Margin % for the quarter that ended in Dec. 2024 was -41.32%.

As of today, Guardant Health's current FCF Yield % is -4.91%.

The historical rank and industry rank for Guardant Health's FCF Margin % or its related term are showing as below:

MEX:GH' s FCF Margin % Range Over the Past 10 Years
Min: -162.95 Med: -76.02 Max: -31.92
Current: -37.43

During the past 9 years, the highest FCF Margin % of Guardant Health was -31.92%. The lowest was -162.95%. And the median was -76.02%.

MEX:GH's FCF Margin % is ranked worse than
72.99% of 211 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.33 vs MEX:GH: -37.43

Guardant Health FCF Margin % Historical Data

The historical data trend for Guardant Health's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardant Health FCF Margin % Chart

Guardant Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-55.10

-76.02

-86.07

-61.26

-37.20

Guardant Health Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-53.40	-22.09	-55.90	-28.86	-41.32

Competitive Comparison of Guardant Health's FCF Margin %

For the Diagnostics & Research subindustry, Guardant Health's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Guardant Health's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Guardant Health's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Guardant Health FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Guardant Health's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-5734.128	/	15412.696
	=	-37.20 %

Guardant Health's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-1739.115	/	4208.972
	=	-41.32 %

Guardant Health FCF Margin % Related Terms

Thank you for viewing the detailed overview of Guardant Health's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Guardant Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (MEX:GH) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

GH:USA 5GH:Germany

Address

3100 Hanover Street, Palo Alto, CA, USA, 94304

Website

https://www.guardanthealth.com

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.